(Reuters) – Patients have once again started taking Aimmune Therapeutics Inc’s peanut allergy drug as some allergy specialists reopen their offices after coronavirus-led lockdowns, the drugmaker’s executives told Reuters on Thursday.
The U.S. launch of the drug, Palforzia, was paused in May as the pandemic forced doctor’s offices to close.
Some allergists have begun putting more than one patient on the treatment, the executives said, adding the company would share more details on the number of prescribers when it reports quarterly earnings.
(Reporting by Manas Mishra in Bengaluru and Carl O’Donnell in New York; Editing by Shinjini Ganguli)
